financetom
Business
financetom
/
Business
/
Lennar Expected to Miss Earnings Estimates for Fiscal Q3, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lennar Expected to Miss Earnings Estimates for Fiscal Q3, Oppenheimer Says
Sep 10, 2025 8:59 AM

11:32 AM EDT, 09/10/2025 (MT Newswires) -- Lennar ( LEN ) is expected to miss earnings estimates for fiscal Q3, with EPS projected at $2.04 versus the Street's estimate of $2.12 amid weaker demand and higher incentives, Oppenheimer said in a note Wednesday.

Q4 guidance may be stronger, as the company could benefit from lower mortgage rates and better cost leverage, but recent stock gains suggest the market may have already priced this in, the investment firm said.

Leverage remains a concern, with adjusted debt levels significantly higher when accounting for land bank obligations, Oppenheimer said.

Adjusted debt-to-capital stands at 72%, the highest in the sector, it added.

A future margin hit is expected in fiscal 2026 due to the MRP land transaction, which could lower gross margins by about 80 basis points and raised Lennar's ( LEN ) costs as the company fully expenses these land deals, according to the note.

Return on equity is likely to stay below peers, with fiscal 2025 ROE projected at just 10%, while achieving the long-term average ROE would require a 50% increase in turnover, which seems unlikely, Oppenheimer analysts noted.

Oppenheimer maintained a perform rating for Lennar ( LEN ).

Price: 136.05, Change: -1.40, Percent Change: -1.02

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CleanCore Solutions Congratulates House of Doge on Successful Go-Public Transaction and Provides Treasury Update
CleanCore Solutions Congratulates House of Doge on Successful Go-Public Transaction and Provides Treasury Update
Oct 13, 2025
In collaboration with House of Doge and its strategic partners 21Shares and Robinhood, CleanCore will gain access to alpha-generating yield strategies designed to enhance treasury performance and long-term asset growth. House of Doge aims to accelerate Dogecoin’s adoption and real-world utility across commerce and paymentsHouse of Doge starts real-world tokenization initiatives, further accelerating the demand for dogecoin        ...
Bicara Therapeutics Says Potential Head, Neck Cancer Drug Gets FDA Breakthrough Therapy Designation
Bicara Therapeutics Says Potential Head, Neck Cancer Drug Gets FDA Breakthrough Therapy Designation
Oct 13, 2025
08:30 AM EDT, 10/13/2025 (MT Newswires) -- Bicara Therapeutics ( BCAX ) said Monday that ficerafusp alfa in combination with pembrolizumab for the treatment of head and neck squamous cell carcinoma, or HNSCC, has received Breakthrough Therapy Designation from the US Food and Drug Administration. The designation shows recognition of human papillomavirus-negative HNSCC as a clear clinical indication within head...
Blackboxstocks Inc. Announces its Merger Target REalloys inks LOI for a 10-Year Offtake Agreement for 15% of Tanbreez Production with Critical Metals Corp. to Strengthen North American Rare Earth Inde
Blackboxstocks Inc. Announces its Merger Target REalloys inks LOI for a 10-Year Offtake Agreement for 15% of Tanbreez Production with Critical Metals Corp. to Strengthen North American Rare Earth Inde
Oct 13, 2025
The LOI is for a 10-year off-take agreement, which plans to provide REalloys with long-term heavy rare earth feedstock from Critical Metals Corp.’s Tanbreez Project in Greenland, one of the world’s most significant deposits. REalloys’ strategic partnership aligns with U.S. and allied priorities to build a fully independent North American mine-to-magnet supply chain. NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE)...
Moderna Says Investigational Cancer Antigen Therapy Shows 'Promising' Early Data
Moderna Says Investigational Cancer Antigen Therapy Shows 'Promising' Early Data
Oct 13, 2025
08:30 AM EDT, 10/13/2025 (MT Newswires) -- Moderna ( MRNA ) said Monday that its investigational cancer antigen therapy, mRNA-4359, in combination with pembrolizumab, has shown promising results in its phase 1/2 trial in certain Melanoma patients. The company said the combination therapy achieved a 24% objective response rate and a 60% disease control rate. Among a subgroup of patients...
Copyright 2023-2026 - www.financetom.com All Rights Reserved